Erick Jimenez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erick Jimenez has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Bradley C. Clark
Masonic Children’s Hospital, University of Minnesota, Minneapolis (B.C.C., E.J.).
4 shared publications - Daniel Cortez
Division of Pediatric Cardiology and Adult Congenital Cardiology, UC Davis Medical Center, Sacramento, USA
3 shared publications - Allison C. Hill
Division of Cardiology, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, USA
2 shared publications - Christopher L. Johnsrude
Department of Pediatrics, Division of Pediatric Cardiology, Norton Children’s Hospital, University of Louisville Louisville, KY
2 shared publications Daniel Cortez
University of Minnesota, Department of Pediatrics, Division of Pediatric Cardiology, Minneapolis, MN, USA; University of California - Davis Medical Center, Division of Pediatric Cardiology, Sacramento, CA, USA
2 shared publicationsMatthew Ambrose
Division of Pediatric Cardiology, Department of Pediatrics, University of Minnesota - Masonic Children's Hospital, 2450 Riverside Avenue S, Minneapolis, MN 55454, USA
2 shared publications
Latest Publications
- 1 October 2025
- Published by Elsevier in Clinics in Perinatology
- Vol. 52 (4) , 709-729
Congenital Heart Block
- 1 October 2025
- Published by Elsevier in Clinics in Perinatology
- Vol. 52 (4) , 709-729
Congenital Heart Block
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (10) , e013437
Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype
BACKGROUND: Marked intellectual and neurodevelopmental delay (INDD) was noted in 6 unrelated patients diagnosed with RYR2 -related catecholaminergic polymorphic ventricular tachycardia (CPVT) from a single center. Patients exhibited similar distinct phenotypic features not previously described. We aimed to determine the prevalence of INDD in CPVT, compare clinical characteristics between patients with CPVT with and without INDD, and investigate the possibility of a unique neurocardiac CPVT phenotype. METHODS: Retrospective combined review of patients with RYR2 -related CPVT diagnosed ≤18 years with and without INDD from a single center and the International Pediatric CPVT Registry. Patients with hypoxic ischemic insult were excluded unless INDD preceded injury. RESULTS: Among a total of 168 patients, INDD was reported in 19 (11.3% [95% CI, 7.0%–17.1%]). When compared with cases without INDD, patients with INDD exhibited distinct features including (1) younger age at onset of symptoms (median 7.0 versus 10.0 years; P =0.04); (2) higher frequency of atrial tachyarrhythmias (84.2% versus 16.3%, P P P =0.001 respectively); (4) cardiac structural changes or systolic dysfunction (36.8% versus 1.3%, P P =0.001). INDD-related RYR2 genetic variants clustered within the central and channel domains and may be specific to certain variants. CONCLUSIONS: This study demonstrates a wider spectrum of RYR2 -related disease, with a subset associated with extracardiac manifestations. Certain RYR2 variants may lead to a neurocardiac phenotype with distinct features that are important to recognize, as these patients may be at higher risk.
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (10) , e013437
Intellectual and Neurodevelopmental Delays in Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: Distinct Characteristics and a More Malignant Neurocardiac Phenotype
BACKGROUND: Marked intellectual and neurodevelopmental delay (INDD) was noted in 6 unrelated patients diagnosed with RYR2 -related catecholaminergic polymorphic ventricular tachycardia (CPVT) from a single center. Patients exhibited similar distinct phenotypic features not previously described. We aimed to determine the prevalence of INDD in CPVT, compare clinical characteristics between patients with CPVT with and without INDD, and investigate the possibility of a unique neurocardiac CPVT phenotype. METHODS: Retrospective combined review of patients with RYR2 -related CPVT diagnosed ≤18 years with and without INDD from a single center and the International Pediatric CPVT Registry. Patients with hypoxic ischemic insult were excluded unless INDD preceded injury. RESULTS: Among a total of 168 patients, INDD was reported in 19 (11.3% [95% CI, 7.0%–17.1%]). When compared with cases without INDD, patients with INDD exhibited distinct features including (1) younger age at onset of symptoms (median 7.0 versus 10.0 years; P =0.04); (2) higher frequency of atrial tachyarrhythmias (84.2% versus 16.3%, P P P =0.001 respectively); (4) cardiac structural changes or systolic dysfunction (36.8% versus 1.3%, P P =0.001). INDD-related RYR2 genetic variants clustered within the central and channel domains and may be specific to certain variants. CONCLUSIONS: This study demonstrates a wider spectrum of RYR2 -related disease, with a subset associated with extracardiac manifestations. Certain RYR2 variants may lead to a neurocardiac phenotype with distinct features that are important to recognize, as these patients may be at higher risk.
- 1 March 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (3) , e013436
Multicenter Results of a Novel Pediatric Pacemaker in Neonates and Infants
BACKGROUND: To address the unmet need for a smaller pacemaker for babies, a specially modified implantable pulse generator was developed containing a Medtronic Micra subassembly in a polymer header connecting to a bipolar epicardial lead. The aim of this study was to report midterm follow-up data and outcomes of patients who underwent implantation of this device. METHODS: Deidentified data were collected from 12 of 15 sites in the United States implanting the pediatric implantable pulse generator between March 2022 and February 2024. All 29 patients at these 12 sites within this timeframe were included in the analysis. RESULTS: The median age at implant was 15 days (range, 0 days to 3 years, including 1 outlier). The median weight was 2.3 kg (range, 1.3–11.4 kg). Gestational age was 28.5 weeks to term, with 23 (79%) patients born prematurely. Of those with anatomic information, 25% had congenital heart disease. The average duration of implant was 325 days (73–808 days). The most recent lead impedance mean was 612 ohms (450–840 ohms), ventricular capture threshold mean was 1 V @ 0.4 ms (range, 0.38–2.75 V), and R-wave sensing mean was 12.5 mV (3.6–20 mV). There were 7 generator explants (24%), removed at 6.5 to 31 months of age. CONCLUSIONS: The pediatric implantable pulse generator can be safely implanted in neonates and infants. This multicenter report demonstrates that the devices remain stable, with effective pacing, normal electrical parameters, and battery longevity aligned with projections. This novel pediatric pacemaker provides a viable alternative to standard-size generators and addresses a vital unmet need for these small patients.
- 1 March 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (3) , e013436
Multicenter Results of a Novel Pediatric Pacemaker in Neonates and Infants
BACKGROUND: To address the unmet need for a smaller pacemaker for babies, a specially modified implantable pulse generator was developed containing a Medtronic Micra subassembly in a polymer header connecting to a bipolar epicardial lead. The aim of this study was to report midterm follow-up data and outcomes of patients who underwent implantation of this device. METHODS: Deidentified data were collected from 12 of 15 sites in the United States implanting the pediatric implantable pulse generator between March 2022 and February 2024. All 29 patients at these 12 sites within this timeframe were included in the analysis. RESULTS: The median age at implant was 15 days (range, 0 days to 3 years, including 1 outlier). The median weight was 2.3 kg (range, 1.3–11.4 kg). Gestational age was 28.5 weeks to term, with 23 (79%) patients born prematurely. Of those with anatomic information, 25% had congenital heart disease. The average duration of implant was 325 days (73–808 days). The most recent lead impedance mean was 612 ohms (450–840 ohms), ventricular capture threshold mean was 1 V @ 0.4 ms (range, 0.38–2.75 V), and R-wave sensing mean was 12.5 mV (3.6–20 mV). There were 7 generator explants (24%), removed at 6.5 to 31 months of age. CONCLUSIONS: The pediatric implantable pulse generator can be safely implanted in neonates and infants. This multicenter report demonstrates that the devices remain stable, with effective pacing, normal electrical parameters, and battery longevity aligned with projections. This novel pediatric pacemaker provides a viable alternative to standard-size generators and addresses a vital unmet need for these small patients.
- 2 December 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (2) , 331-337
Thromboembolic Complications From Atrial Fibrillation and Atrial Flutter in Pediatrics and Young Adults: A Multicenter Study
Background: Atrial fibrillation and atrial flutter are relatively rare in young people and the incidence of thromboembolic complications is unknown. These issues contribute to the limited utility of present guidelines regarding anticoagulation in this population.Objective: To report the number of thromboembolic complications in a cohort of pediatric and young adult patients presenting with atrial fibrillation (AFib) or atrial flutter (AFl) while also assessing anticoagulation practice in a multicenter cohort of young patients with these arrhythmias.Methods: Multicenter, retrospective cohort of patients aged < 25 years old who presented with atrial flutter (AFl) or atrial fibrillation (AFib) between 2000 and 2019 to several large, quaternary pediatric centers, excluding episodes occurring within 30 days of an invasive cardiac procedure.Results: There were 311 episodes of AFib/AFl among 210 patients with a median age of 17 (IQR 14, 20) years. Structural heart disease (SHD) was present in 120 patients (57%) and 20 patients (10%) had a primary cardiomyopathy. Twelve AFib/AFl episodes (8 with AFL, 4 with AFib) were associated with a thrombus, of which 8 (67%) patients had SHD, 2 (17%) had cardiomyopathy and 5 (42%) ventricular dysfunction. The CHADSVASc score was 0–3 for all patients with a thrombus. Of patients with no thrombus at presentation who were cardioverted, 102 (34%) patients were discharged on aspirin and 80 (27%) on anticoagulation. Two patients had symptoms concerning for a thromboembolic event on follow‐up, but none had a newly documented thrombus.Conclusions: Thromboembolic complications occur in children and young adults presenting with AFib/AFl. The majority are associated with SHD, cardiomyopathy, and/or ventricular dysfunction. CHADSVASc was calculated for each patient and was of limited utility. Thromboembolic complications at follow up after cardioversion are rare, and anticoagulation strategies at discharge varied.
- 2 December 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (2) , 331-337
Thromboembolic Complications From Atrial Fibrillation and Atrial Flutter in Pediatrics and Young Adults: A Multicenter Study
Background: Atrial fibrillation and atrial flutter are relatively rare in young people and the incidence of thromboembolic complications is unknown. These issues contribute to the limited utility of present guidelines regarding anticoagulation in this population.Objective: To report the number of thromboembolic complications in a cohort of pediatric and young adult patients presenting with atrial fibrillation (AFib) or atrial flutter (AFl) while also assessing anticoagulation practice in a multicenter cohort of young patients with these arrhythmias.Methods: Multicenter, retrospective cohort of patients aged < 25 years old who presented with atrial flutter (AFl) or atrial fibrillation (AFib) between 2000 and 2019 to several large, quaternary pediatric centers, excluding episodes occurring within 30 days of an invasive cardiac procedure.Results: There were 311 episodes of AFib/AFl among 210 patients with a median age of 17 (IQR 14, 20) years. Structural heart disease (SHD) was present in 120 patients (57%) and 20 patients (10%) had a primary cardiomyopathy. Twelve AFib/AFl episodes (8 with AFL, 4 with AFib) were associated with a thrombus, of which 8 (67%) patients had SHD, 2 (17%) had cardiomyopathy and 5 (42%) ventricular dysfunction. The CHADSVASc score was 0–3 for all patients with a thrombus. Of patients with no thrombus at presentation who were cardioverted, 102 (34%) patients were discharged on aspirin and 80 (27%) on anticoagulation. Two patients had symptoms concerning for a thromboembolic event on follow‐up, but none had a newly documented thrombus.Conclusions: Thromboembolic complications occur in children and young adults presenting with AFib/AFl. The majority are associated with SHD, cardiomyopathy, and/or ventricular dysfunction. CHADSVASc was calculated for each patient and was of limited utility. Thromboembolic complications at follow up after cardioversion are rare, and anticoagulation strategies at discharge varied.
- Open Access
- 15 October 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (12) , 2491-2493
Contact allergic dermatitis to skin adhesive after CIED upgrade procedure
Introduction: The utilization of skin adhesives for closure is typically secondary to its noninvasive application and aesthetic benefits. Allergic reactions to Dermabond™ can occur, though there are no reported cases in pediatric patients following cardiac implantable electronic device (CIED) implantation. The allergic reaction to skin glues is typically to cyanoacrylates, the primary component of Dermabond™.Methods and Results: This report describes severe allergic contact dermatitis due to sensitization to cyanoacrylate in an 18‐year‐old with repaired congenital heart disease and postoperative atrioventricular block following CIED upgrade procedure.Conclusion: This demonstrates the importance of prompt diagnosis of allergic contact dermatitis, which can be confused with local infections.
- 15 October 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (12) , 2491-2493
Open AccessContact allergic dermatitis to skin adhesive after CIED upgrade procedure
Introduction: The utilization of skin adhesives for closure is typically secondary to its noninvasive application and aesthetic benefits. Allergic reactions to Dermabond™ can occur, though there are no reported cases in pediatric patients following cardiac implantable electronic device (CIED) implantation. The allergic reaction to skin glues is typically to cyanoacrylates, the primary component of Dermabond™.Methods and Results: This report describes severe allergic contact dermatitis due to sensitization to cyanoacrylate in an 18‐year‐old with repaired congenital heart disease and postoperative atrioventricular block following CIED upgrade procedure.Conclusion: This demonstrates the importance of prompt diagnosis of allergic contact dermatitis, which can be confused with local infections.
- Open Access
- 4 October 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (11) , 1310-1314
Catheter ablation of atrioventricular nodal reentrant tachycardia, when AVNRT presented as a fetus or infant
Background: Atrioventricular nodal reentrant tachycardia (AVNRT) does not commonly present during infancy. Although relative safety of catheter ablation of AVNRT has been demonstrated in pediatrics, this procedure is rarely indicated in children <15 kg.Methods: Retrospective review of seven cases of AVNRT that presented in children younger than 1 year of age and required catheter ablation for definitive management. Electrophysiology (EP) study was planned with two or three catheters. Area of ablation determined by voltage mapping, propagation sinus wave collision and slow pathway potential location. Ablation performed with cryothermal energy. No fluoroscopy was used.Results: Presentation ranged from 36 weeks of gestation to 11 months of age. Two presented in fetal life and two in the neonatal period. The median age of ablation was 20 months (range 17–31 months). The median weight at ablation was 11.4 kg (range 8.9–14.9 kg). Median follow‐up time was 16 months. All had typical AVNRT. The median tachycardia cycle length was 216 ms. 100% successful rate using cryoablation. No complications. No recurrence of tachycardia during the follow‐up period.Conclusion: Slow AV nodal pathway cryoablation may be safely performed, with good short and medium‐term outcomes in patients under 15 kg.
- 4 October 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (11) , 1310-1314
Open AccessCatheter ablation of atrioventricular nodal reentrant tachycardia, when AVNRT presented as a fetus or infant
Background: Atrioventricular nodal reentrant tachycardia (AVNRT) does not commonly present during infancy. Although relative safety of catheter ablation of AVNRT has been demonstrated in pediatrics, this procedure is rarely indicated in children <15 kg.Methods: Retrospective review of seven cases of AVNRT that presented in children younger than 1 year of age and required catheter ablation for definitive management. Electrophysiology (EP) study was planned with two or three catheters. Area of ablation determined by voltage mapping, propagation sinus wave collision and slow pathway potential location. Ablation performed with cryothermal energy. No fluoroscopy was used.Results: Presentation ranged from 36 weeks of gestation to 11 months of age. Two presented in fetal life and two in the neonatal period. The median age of ablation was 20 months (range 17–31 months). The median weight at ablation was 11.4 kg (range 8.9–14.9 kg). Median follow‐up time was 16 months. All had typical AVNRT. The median tachycardia cycle length was 216 ms. 100% successful rate using cryoablation. No complications. No recurrence of tachycardia during the follow‐up period.Conclusion: Slow AV nodal pathway cryoablation may be safely performed, with good short and medium‐term outcomes in patients under 15 kg.
- 5 September 2023
- Published by Springer Nature in Pediatric Cardiology
- Vol. 44 (8) , 1-3
Twin JET Engines: Multiple JET Foci in Patient With Heterotaxy
- 5 September 2023
- Published by Springer Nature in Pediatric Cardiology
- Vol. 44 (8) , 1-3
Twin JET Engines: Multiple JET Foci in Patient With Heterotaxy
- Open Access
- 18 April 2022
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 22 (4) , 182-185
Reduction of fluoroscopy in conduction system pacing guided by electroanatomical mapping in pediatrics and congenital heart disease
- 18 April 2022
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 22 (4) , 182-185
Open AccessReduction of fluoroscopy in conduction system pacing guided by electroanatomical mapping in pediatrics and congenital heart disease
- 1 September 2021
- Published by Elsevier in Journal of Electrocardiology
- Vol. 68, 80-84
Vectorcardiography as a prognostic tool in hypertrophic cardiomyopathy
- 1 September 2021
- Published by Elsevier in Journal of Electrocardiology
- Vol. 68, 80-84
Vectorcardiography as a prognostic tool in hypertrophic cardiomyopathy
- Open Access
- 26 September 2020
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 26 (2)
Peripartum management of a patient with catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal cardiac channelopathy characterized by episodes of ventricular tachycardia (VT) during exercise or in stressful situations. As the peripartum period creates a stressful environment, we describe our approach of this rare condition in a very common situation, child birth.
- 26 September 2020
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 26 (2)
Open AccessPeripartum management of a patient with catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal cardiac channelopathy characterized by episodes of ventricular tachycardia (VT) during exercise or in stressful situations. As the peripartum period creates a stressful environment, we describe our approach of this rare condition in a very common situation, child birth.